The global cardiac biomarkers market size was estimated at USD 20.81 billion in 2025 and is expected to reach USD 49.31 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The market is driven by the rising prevalence of cardiovascular diseases such as acute coronary syndrome, myocardial infarction, and heart failure, increasing the demand for early and accurate diagnosis.
Advancements in high-sensitivity troponin assays and multi-marker testing have improved clinical decision-making and patient outcomes. In addition, expanding use of point-of-care testing, supportive reimbursement frameworks, and an aging population with higher cardiac risk continue to support market expansion globally.
Cardiovascular diseases are one of the major causes of death globally. According to the World Health Organization (WHO) survey in 2023, it was stated that approximately 17.9 million deaths due to cardiac disorders were reported each year. The prevalence of these conditions continues to rise due to an aging population, obesity, diabetes, and hypertension, leading to an increasing number of individuals at risk of heart attack or heart failure. The growing burden of cardiovascular diseases has created a critical need for early detection, accurate diagnosis, and effective patient monitoring. This is where cardiac biomarkers play a vital role. Biomarkers such as troponin, Creatine Kinase-MB (CK-MB), and myoglobin are essential for detecting myocardial injury and assessing disease severity and therefore help in making treatment decisions.
The rising demand for point-of-care (POC) cardiac testing kits is further expected to propel the growth in the cardiac biomarkers Market. Traditionally, the diagnosis of cardiovascular diseases relied on centralized laboratory testing, which requires specialized instruments and trained personnel. These conventional systems can delay diagnosis and treatment, particularly in acute settings such as emergency department admissions for chest pain or suspected myocardial infarction. Such delays can have serious clinical consequences, as timely identification of cardiac events is critical for initiating interventions and improving patient survival rates. POC cardiac testing kits enable quick diagnostic results for making timely decisions directly at the site of patient care, including emergency rooms, cardiology clinics, and in-home-based settings. Key biomarkers such as troponin, natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) are now measurable at the point of care, allowing clinicians to make faster treatment decisions. For instance, POC cTn tests typically provide results within 10 to 20 minutes.
Emerging biomarkers, including soluble suppression of tumorigenicity-2 (sST2), heart-type fatty acid-binding protein (H-FABP), Galectin-3, and growth differentiation factor-15 (GDF-15), are gaining attention for their potential clinical utility. For instance, a study published by MDPI in August 2025 reported that the biomarkers GDF-15, sST2, suPAR, and H-FABP demonstrated promising potential across a range of cardiovascular diseases.
These novel biomarkers not only reflect different aspects of cardiovascular physiology but also offer the potential to improve early diagnosis and monitoring of treatment response. Advances in technology, including high-sensitivity assays and nanotechnology-based sensors, have further enhanced the ability to detect these biomarkers at very low concentrations, enabling faster and more accurate clinical decision-making. In addition, combining multiple biomarkers into panels allows clinicians to gain a more comprehensive understanding of a patient’s cardiovascular status, moving toward more personalized and precise approaches to care. As research continues and more evidence emerges, these novel cardiac biomarkers are expected to play an important role in improving outcomes for patients with heart disease.
Advancements in high-sensitivity troponin assays and multi-marker testing have improved clinical decision-making and patient outcomes. In addition, expanding use of point-of-care testing, supportive reimbursement frameworks, and an aging population with higher cardiac risk continue to support market expansion globally.
Cardiovascular diseases are one of the major causes of death globally. According to the World Health Organization (WHO) survey in 2023, it was stated that approximately 17.9 million deaths due to cardiac disorders were reported each year. The prevalence of these conditions continues to rise due to an aging population, obesity, diabetes, and hypertension, leading to an increasing number of individuals at risk of heart attack or heart failure. The growing burden of cardiovascular diseases has created a critical need for early detection, accurate diagnosis, and effective patient monitoring. This is where cardiac biomarkers play a vital role. Biomarkers such as troponin, Creatine Kinase-MB (CK-MB), and myoglobin are essential for detecting myocardial injury and assessing disease severity and therefore help in making treatment decisions.
The rising demand for point-of-care (POC) cardiac testing kits is further expected to propel the growth in the cardiac biomarkers Market. Traditionally, the diagnosis of cardiovascular diseases relied on centralized laboratory testing, which requires specialized instruments and trained personnel. These conventional systems can delay diagnosis and treatment, particularly in acute settings such as emergency department admissions for chest pain or suspected myocardial infarction. Such delays can have serious clinical consequences, as timely identification of cardiac events is critical for initiating interventions and improving patient survival rates. POC cardiac testing kits enable quick diagnostic results for making timely decisions directly at the site of patient care, including emergency rooms, cardiology clinics, and in-home-based settings. Key biomarkers such as troponin, natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) are now measurable at the point of care, allowing clinicians to make faster treatment decisions. For instance, POC cTn tests typically provide results within 10 to 20 minutes.
Emerging biomarkers, including soluble suppression of tumorigenicity-2 (sST2), heart-type fatty acid-binding protein (H-FABP), Galectin-3, and growth differentiation factor-15 (GDF-15), are gaining attention for their potential clinical utility. For instance, a study published by MDPI in August 2025 reported that the biomarkers GDF-15, sST2, suPAR, and H-FABP demonstrated promising potential across a range of cardiovascular diseases.
These novel biomarkers not only reflect different aspects of cardiovascular physiology but also offer the potential to improve early diagnosis and monitoring of treatment response. Advances in technology, including high-sensitivity assays and nanotechnology-based sensors, have further enhanced the ability to detect these biomarkers at very low concentrations, enabling faster and more accurate clinical decision-making. In addition, combining multiple biomarkers into panels allows clinicians to gain a more comprehensive understanding of a patient’s cardiovascular status, moving toward more personalized and precise approaches to care. As research continues and more evidence emerges, these novel cardiac biomarkers are expected to play an important role in improving outcomes for patients with heart disease.
Global Cardiac Biomarkers Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, the analyst has segmented the cardiac biomarkers market based on type, application, end use, and region.Type Outlook (Revenue, USD Million, 2021-2033)
- Troponin
- CK-MB
- Myoglobin
- BNP and NT-proBNP
- Others
Application Outlook (Revenue, USD Million, 2021-2033)
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Laboratory Testing
- Point of Care Testing
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Type Business Analysis
Chapter 5. Application Business Analysis
Chapter 6. End Use Business Analysis
Chapter 7. Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Cardiac Biomarkers market report include:- Abbott
- Quidel Corporation
- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Randox Laboratories
- Creative Diagnostics
- Life Diagnostics, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | February 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 20.81 Billion |
| Forecasted Market Value ( USD | $ 49.31 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
